Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Trial Profile

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 18F DCFPyL (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 04 Jun 2019 According to a trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology, this study is open with two patients enrolled at the time of submission and one patient has completed his initial PyL PET/CT scan.
    • 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 23 May 2019 According to a Progenics Pharmaceuticals media release, data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, which will be held from May 31 to June 4, 2019 in Chicago, Illinois.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top